Sign In
Buy RLMD
$6.33
-0.0900 (-1.40%)
At Close: Jun 03, 2026
Relmada Therapeutics, Inc. (RLMD) CEO Sergio Traversa on Q3 2021 Results - Earnings Call Transcript
10:21pm, Thursday, 11'th Nov 2021
Relmada Therapeutics, Inc. (RLMD) CEO Sergio Traversa on Q3 2021 Results - Earnings Call Transcript
CORAL GABLES, Fla., Oct. 4, 2021 /PRNewswire/ -- Relmada Therapeutics, Inc. (NASDAQ: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today provided
Relmada Therapeutics to Present at the Morgan Stanley 19th Annual Global Healthcare Conference
08:15am, Friday, 03'rd Sep 2021
CORAL GABLES, Fla., Sept. 3, 2021 /PRNewswire/ -- Relmada Therapeutics, Inc. (NASDAQ: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announce
Relmada Therapeutics, Inc. (RLMD) CEO Sergio Traversa on Q2 2021 Results - Earnings Call Transcript
10:36pm, Tuesday, 10'th Aug 2021
Relmada Therapeutics, Inc. (RLMD) CEO Sergio Traversa on Q2 2021 Results - Earnings Call Transcript
Down 22.7% in 4 Weeks, Here's Why You Should You Buy the Dip in Relmada Therapeutics, Inc. (RLMD)
11:24am, Friday, 30'th Jul 2021
Relmada Therapeutics, Inc. (RLMD) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street ana
Relmada Sees Price Target Bump From Leerink, Truist After Positive Data From MDD Candidate
12:41pm, Tuesday, 27'th Jul 2021
SVB Leerink maintains an Outperform rating on Relmada Therapeutics Inc (NASDAQ: RLMD) shares as the Human Liability Potential study data was about "as good as we could have hoped for," with no ev
Here's Why Relmada Therapeutics Stock Popped Today
12:10pm, Tuesday, 27'th Jul 2021
Results from a human abuse potential study with REL-1017 exceeded expectations.
RLMD Stock Increases Over 37% Intraday: Why It Happened
11:12am, Tuesday, 27'th Jul 2021
The stock price of Relmada Therapeutics Inc (NASDAQ: RLMD) increased by over 37% during intraday trading. This is why it happened.
Relmada Therapeutics Announces Top-Line Results of Study Evaluating REL-1017 vs Oxycodone for Abuse Potential
07:35am, Tuesday, 27'th Jul 2021
NEW YORK, July 27, 2021 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), announced today top-li
Relmada Therapeutics In-Licenses Psilocybin Program From Arbormentis
12:37pm, Tuesday, 20'th Jul 2021
Relmada Therapeutics Inc (NASDAQ: RLMD) has acquired the development and commercial rights to novel psilocybin and derivate program from Arbormentis LLC in all ex-Asia territories, including the
NEW YORK, July 20, 2021 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced the ac
Relmada Therapeutics Announces Participation in Goldman Sachs 42nd Annual Global Healthcare Conference
08:30am, Monday, 07'th Jun 2021
NEW YORK, June 7, 2021 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that Ser
Relmada Therapeutics Announces Participation in Jefferies Virtual Healthcare Conference
08:30am, Tuesday, 01'st Jun 2021
NEW YORK, June 1, 2021 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that Serg
Relmada Therapeutics Announces Oral Poster Presentation on REL-1017 at 2021 American Society of Clinical Psychopharmacology Annual Meeting
08:00am, Wednesday, 26'th May 2021
NEW YORK, May 26, 2021 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that clin
Relmada Therapeutics, Inc. (RLMD) CEO Sergio Traversa on Q1 2021 Results - Earnings Call Transcript
10:12pm, Wednesday, 12'th May 2021
Relmada Therapeutics, Inc. (RLMD) CEO Sergio Traversa on Q1 2021 Results - Earnings Call Transcript
